The Globe and Mail

Alpha-1 Antitrypsin Deficiency Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, and Companies by DelveInsight

Alpha-1 Antitrypsin Deficiency Companies are Kamada Pharmaceuticals, Arrowhead Pharmaceuticals, Takeda, Mereo BioPharma, AstraZeneca, Inhibrx, Novo Nordisk, and others. (Albany, USA) DelveInsight's ...
American Lung Association

Overcoming Alpha-1: A Powerful Story of Survival, Treatment and Triumph

Bonnie shares her story of being diagnosed with Alpha-1 Antitrypsin Deficiency and learning to manage the rare disease.
CMAJ

Alpha-1 antitrypsin deficiency: a commonly overlooked cause of lung disease

Sarah K. Brode, Simon C. Ling and Kenneth R. Chapman In this review, we highlight the pathogenesis, clinical features, diagnosis and treatment of alpha-1 antitrypsin deficiency. The evidence used in ...
UUHC Health Feed

Alpha-1 Antitrypsin Deficiency

Alpha-1 antitrypsin (AAT) deficiency is a genetic disease where your body doesn’t make enough normal functioning AAT. AAT is a protein your liver makes. AAT has many important roles in your body, ...

Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Sanofi: Sanofi's efdoralprin alfa earns orphan designation in the EU for alpha-1 antitrypsin deficiency related emphysema

Sanofi's efdoralprin alfa earns orphan designation in the EU for alpha-1 antitrypsin deficiency related emphysema Additional orphan designation reinforces Sanofi's commitment to developing treatments ...